DELRAY BEACH, Fla., Nov. 7, 2025 /PRNewswire/ — The global Preimplantation Genetic Testing Market, valued at US$636.4 million in 2024, stood at US$690.2 million in 2025 and is projected to advance at a resilient CAGR of 10.5% from 2025 to 2030, culminating in a forecasted valuation of US$1,135.0 million by the end of the period. The market is driven by the rising prevalence of genetic and chromosomal disorders, increasing infertility rates, and growing adoption of assisted reproductive technologies (ART). The increasing use of advanced genomic tools, such as next-generation sequencing (NGS) and array-based technologies, is further enhancing the accuracy and reliability of embryo screening. Additionally, increasing awareness of genetic health, coupled with the demand for improved IVF success rates, is propelling the adoption of preimplantation genetic testing in fertility clinics worldwide.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Browse in-depth TOC on “
Preimplantation Genetic Testing Market
“
200 – Tables
45 – Figures
300 – Pages
By procedure type, the preimplantation genetic testing market is divided by procedure type into preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). This growth is primarily driven by the increasing use of PGS to detect chromosomal abnormalities before embryo transfer. End users, such as fertility clinics and IVF centers, are increasingly adopting comprehensive, high-throughput screening methods to boost implantation success and lessen the chance of genetic disorders. The adoption of next-generation sequencing (NGS) and array-based platforms has greatly enhanced accuracy, speed, and dependability. Moreover, ongoing product innovations and the availability of automated, ready-to-use screening options are further encouraging adoption in clinical environments.
By technology, the preimplantation genetic testing market is segmented into next-generation sequencing, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP) analysis. The next-generation sequencing (NGS) segment accounted for the largest share of the preimplantation genetic testing market in 2024 and is expected to maintain its dominance during the forecast period. The market’s growth is driven by the increasing adoption of NGS for comprehensive chromosomal and single-gene disorder screening in embryos prior to implantation.
By enabling high-throughput analysis and precise detection of genetic abnormalities, NGS offers superior accuracy, sensitivity, and resolution compared to traditional techniques such as FISH and PCR. The technology enables the simultaneous screening of multiple genetic conditions, significantly enhancing embryo selection and improving IVF success rates. Additionally, ongoing improvements in sequencing platforms and bioinformatics tools are boosting workflow efficiency, making NGS-based preimplantation testing a key technique in precision reproductive medicine.
By distribution channel, the market for orthopedic braces and support is divided into hospitals & surgical centers, orthopedic clinics, pharmacies & retailers, e-commerce platforms, DME dealers, and other distribution channels. Hospitals and surgical centers play a crucial role in advancing the orthopedic braces and supports market due to several key factors. The rising number of orthopedic surgeries, such as joint replacements, ligament repairs, and fracture treatments, increases the demand for post-operative bracing solutions to support recovery, immobilization, and rehabilitation. These facilities often serve as the initial point of care where physicians prescribe braces as part of comprehensive treatment plans, especially for trauma, sports injuries, and chronic musculoskeletal conditions. The use of advanced orthopedic care protocols that emphasize early mobilization and conservative therapy further encourages brace adoption. Additionally, reimbursement options for hospital-based treatments and post-surgical orthopedic devices enhance patient access. These centers also benefit from collaborations with device manufacturers, which help ensure a steady supply of high-quality, clinically approved braces for both acute and long-term use.
By geography, The APAC region is expected to see the fastest growth in the preimplantation genetic testing market. This growth is driven by the rising rates of infertility, increased awareness of genetic diseases, and greater adoption of assisted reproductive technologies like IVF. Additionally, government initiatives focused on enhancing reproductive healthcare and increasing access to advanced fertility treatments are further fueling market expansion. Moreover, leading international and regional companies are strengthening their presence through collaborations, partnerships, and technology integrations to seize emerging opportunities across the region.
Request Sample Pages :
https://www.marketsandmarkets.com/requestsampleNew.asp?id=605
in the preimplantation genetic testing market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), CooperCompanies (US), Revvity (US), Abbott (US), Takara Bio Inc. (Japan), and QIAGEN (Germany), among others.
Illumina, Inc. (US):
Illumina is a leading player in the preimplantation genetic testing market, recognized for its advanced sequencing platforms, consumables, and data analysis solutions. The company’s next-generation sequencing (NGS) technologies enable highly accurate detection of chromosomal abnormalities, single-gene mutations, and structural variants in embryos. Illumina continues to enhance its portfolio through technological innovations, such as the NovaSeq and NextSeq platforms, along with specialized workflows like VeriSeq, which are designed for reproductive health applications. Strategic collaborations and R&D investments strengthen its position in clinical genomics, enabling faster and more comprehensive embryo screening. By integrating automation and informatics, Illumina enables fertility clinics and genetic testing laboratories to enhance diagnostic precision, streamline IVF workflows, and improve patient outcomes in reproductive medicine.
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific is a key contributor to the preimplantation genetic testing market, offering a comprehensive suite of instruments, reagents, and software designed for reproductive genetics. The company’s Ion Torrent sequencing technology and Ion ReproSeq PGT kits offer reliable, high-throughput genomic analysis of embryos, enabling the accurate detection of aneuploidies and monogenic disorders. The company focuses on integrating NGS workflows with advanced bioinformatics to deliver end-to-end solutions for IVF laboratories. Continuous product development, combined with strategic partnerships and global reach, allows Thermo Fisher to expand its presence in the reproductive health domain. With a strong emphasis on workflow automation, data accuracy, and scalability, the company plays a pivotal role in advancing genetic screening and improving IVF success rates worldwide.
Agilent Technologies, Inc. (US)
Agilent Technologies holds a notable position in the preimplantation genetic testing market, leveraging its strengths in genomics, microarrays, and bioinformatics. The company’s high-resolution array comparative genomic hybridization (aCGH) and next-generation sequencing tools support comprehensive chromosomal and genomic analysis in embryo testing. Agilent’s SurePrint microarrays and SureFISH platforms are widely used for high-confidence genomic profiling and structural variant detection. Through continuous innovation, strategic collaborations, and software integration, Agilent enhances workflow efficiency and diagnostic reliability for reproductive genetics applications. Its global distribution network and commitment to quality empower fertility clinics and genetic laboratories to achieve reproducible, precise, and scalable results, solidifying Agilent’s position as a trusted technology partner in the preimplantation genetic testing market.
For more information, Inquire Now!
Related Reports:
Next Generation Sequencing Market
Life Science Instrumentation Market
Get access to the latest updates on Preimplantation Genetic Testing Companies and Preimplantation Genetic Testing Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/preimplantation-genetic-testing-market-worth-1-135-0-million-by-2030-with-10-5-cagr–marketsandmarkets-302608319.html
SOURCE MarketsandMarkets
